Forest’s Namenda To Get Label Update After Pediatric Program Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
But Alzheimer’s indication for Namenda and extended-release version will get six months of pediatric exclusivity with a pending NDA for a combo-treatment eligible for the same perks.
You may also be interested in...
Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says
Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.